InterCure Ltd. (NASDAQ:INCR - Get Free Report) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 17,800 shares, a decrease of 12.7% from the September 30th total of 20,400 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 24,800 shares, the short-interest ratio is currently 0.7 days.
InterCure Price Performance
Shares of InterCure stock traded up $0.01 during trading on Tuesday, reaching $1.74. 22,442 shares of the company's stock were exchanged, compared to its average volume of 53,892. The firm's 50-day moving average price is $1.92 and its 200 day moving average price is $2.31. The company has a market cap of $79.30 million, a P/E ratio of 13.31 and a beta of 1.50. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.15 and a current ratio of 1.78. InterCure has a 1-year low of $0.99 and a 1-year high of $3.72.
Institutional Investors Weigh In On InterCure
A number of hedge funds have recently made changes to their positions in the stock. Tidal Investments LLC acquired a new stake in shares of InterCure during the first quarter valued at about $883,000. AdvisorShares Investments LLC acquired a new position in shares of InterCure in the 2nd quarter valued at about $218,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of InterCure by 30.9% during the 2nd quarter. Renaissance Technologies LLC now owns 45,300 shares of the company's stock worth $91,000 after buying an additional 10,700 shares in the last quarter. 8.34% of the stock is currently owned by institutional investors and hedge funds.
InterCure Company Profile
(
Get Free Report)
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider InterCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InterCure wasn't on the list.
While InterCure currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
